A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Trial Profile

A phase 1/1b trial of PUR1900 for treatment of fungal infections in cystic fibrosis patients

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs PUR 1900 (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2017 According to a Pulmatrix media release, the company plans to initiate this study in 2017.
    • 10 Mar 2017 According to a Pulmatrix media release, the company plans to read out the data from trial in 2017.
    • 17 Jan 2017 According to a Pulmatrix media release, the U.S. Food & Drug Administration has designated PUR1900 as a Qualified Infectious Disease Product for the treatment of fungal infections in the lungs of cystic fibrosis patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top